Merck stops phase 3 TIGIT trial in lung cancer for futility—and sees immune side effects again

Merck & Co.’s TIGIT program has suffered another setback. Months after shuttering a phase 3 melanoma trial, the Big Pharma has terminated a pivotal lung cancer study after an interim review revealed efficacy and safety problems.